Keytruda Wins EU Approval for Early Lung Cancer Treatment

The European Commission (EC) has granted approval for Merck & Co. 's Keytruda (pembrolizumab), known as the MSD outside the U.S. and Canada, for treating resectable non-small cell lung cancer (NSCLC) patients, who are at high risk – a  breakthrough in lung cancer care. 

What does the approval cover?

In Europe Keytruda is now approved to be used in adults to treat NSCLC, with tumors of ≥4 cm or with lymph node involvement. The regimen follows a three-phase strategy inclusive of Keytruda followed by chemo before surgery, a surgical intervention and a post-op Keytruda monotherapy for the high-risk patients with an increased vulnerability to relapse. This marks the first approval of an anti-PD-1/PD-L1 therapy for early stage NSCLC. 

Why does Merck’s Keytruda matter? 

Despite surgical intervention, lung cancer continues to be a major contributor to global cancer mortality due to its high relapse-rate. Treatment options were almost lacking or not available for those patients who suffered from resectable NSCLC, especially those with sizable tumors or lymph node involvement. The approval enables Keytruda to deliver a new perioperative approach which unlocks a breakthrough for those high-risk patients with resectable NSCLC. 

Backed by Keynote-671, the perioperative strategy offered by Keytruda assures 28% survival rate in comparison to the traditional treatment methods. Based on the data collected, with a minimum follow-up of 28.9 months, the study revealed a hazard ratio of 0.72, with observed benefits irrespective of PD-L1status. 

The approval of Merck’s Keytruda marks a significant step in therapeutic innovation and sets a new standard – a novel foundational perioperative option resectable NSCLC, echoing the trend of immunotherapies upstream. 

Key Details and Clinical Safety Conditions

The European Commission announced its decision on Keytruda on March 28, 2024 along with certain key details to be considered. 

• The regimen begins with neoadjuvant Keytruda along with platinum-based chemotherapy before surgery. This will be followed by surgical intervention and adjuvant Keytruda alone. 

• The approval is for adults with resectable NSCLC, at high-risk, based on tumor diameter (≥4 cm) and the status of lymph nodes.

• According to the Keynote-671 study – visible adverse effects were seen in 34% of 396 patients. This included at least 2% of patients who were affected by pneumonia (4.8%), venous thromboembolism (3.3%), and anemia (2%). Fatal adverse effects occurred in 1.3% of patients with 0.8% of unknown causes and 03.% of both sepsis and immune-related lung disease. 

What Keytruda approval means for patients and clinicians

European clinicians now have a new treatment paradigm for patients with resectable NSCLC and elevated recurrence risk. Incorporating immunotherapy into both before and after surgery shows a significant shift in strategy – aiming at early intervention rather than awaiting the condition to worsen. 

For patients, the approval arrived as a message of optimism. While surgical intervention remains the cornerstone of curative treatment, addition of Keytruda offers a promising path, with higher possibilities of boosting survival prospects. However, despite the promise, careful selection of patients and continued surveillance should be carried out related to immune-related side effects, like pneumonitis, thromboembolic events and anemia. Hence, in order to optimize outcomes, it is curricula to ensure patient-involvement in decision-making, to transparency in terms of the risk factors.

What challenges remain for Keytruda’s long-term impacts?

Although the approval is supported by the robust survival benefits, further clarity is needed for several critical aspects. 

• Long-term durability of the benefits promised – beyond ~30 months follow-up

• While approved, rollout across Europe is mixed. Adoption is slowed due to reimbursement hurdles and regional access issues. 

• Optimal patient selection – creation of biomarkers

• Effective management of adverse effects in the perioperative phrase is crucial. 

• Comparative cost-effectiveness in the early stage.

Conclusion

Merck’s Keytruda has achieved a major win in Europe, opening a new successful chapter for early stage NSCLC patients at high-risk of relapse. This regimen, combining pre-operative neoadjuvant Keytruda with platinum chemo with post-operative adjuvant Keytruda marks the first European approved PD-1 therapy in the surgical lung cancer setting. While clinical caution remains crucial, this regulatory milestone underscores a broader shift towards early immunotherapy use and enhancesKeytruda’s dominant position in the field. In parallel with Keytruda’s success, new approaches such as Novocure’s therapy delaying lung cancer metastasis to the brain by 10 months underscores the rapid progress across the oncology landscape. 

FAQs

1. What is Keytruda and how does it work?

Keytruda (pembrolizumab) is an immune checkpoint inhibitor that blocks PD-1 on T-cells, restoring immune recognition of cancer cells. 

2. What does the new European approval of Keytruda cover?

The European Commission has authorized neoadjuvant Keytruda combined with platinum chemotherapy before surgery and standalone adjuvant Keytruda afterward. This is approved only for adults with resectable non-small cell lung cancer at high risk of relapse. 

3. How effective is Keytruda for NSCLC?

According to results from the Phase III Keynote-671 study, the Keytruda based regimen led to 28% reduction in mortality risk and 41% decrease in likelihood of recurrence or death by traditional chemotherapy.

4. How does Keytruda benefit lung cancer patients in Europe?

The decision provides a meaningful advancement for high-risk early stage NSCLC patients. Clinicians in Europe can now offer these patients a new perioperative immunotherapy that may enhance long-term outcomes.